EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer

Pénélope Desroys du Roure iD, Laurie Lajoie iD, Aude Mallavialle iD, Lindsay B Alcaraz iD, Hanane Mansouri, Lise Fenou iD, Véronique Garambois, Lucie Rubio, Timothée David iD, Loïs Coenon iD, Florence Boissière-Michot iD, Marie-Christine Chateau iD und 10 weitere

Journal for ImmunoTherapy of Cancer · 2024

DOI: 10.1136/jitc-2023-007135 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Pénélope Desroys du Roure und 21 weiteren Autor:innen. Beteiligte Einrichtung: IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Antineoplastic Agents, Benzamides, Nitriles. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Inserm Transfert, Ligue Régionale du Gard, Ligue Régionale de l’Herault.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Triple-negative breast cancer (TNBC) prognosis is poor. Immunotherapies to enhance the antibody-induced natural killer (NK) cell antitumor activity are emerging for TNBC that is frequently immunogenic. The aspartic protease cathepsin D (cath-D), a tumor cell-associated extracellular protein with protumor activity and a poor prognosis marker in TNBC, is a prime target for antibody-based therapy to induce NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC). This study investigated whether Fc-engineered anti-cath-D antibodies trigger ADCC, their impact on antitumor efficacy and tumor-infiltrating NK cells, and their relevance for combinatory therapy in TNBC.

Methods

Cath-D expression and localization in TNBC samples were evaluated by western blotting, immunofluorescence, and immunohistochemistry. The binding of human anti-cath-D F1M1 and Fc-engineered antibody variants, which enhance (F1M1-Fc + ) or prevent (F1M1-Fc − ) affinity for CD16a, to secreted human and murine cath-D was analyzed by ELISA, and to CD16a by surface plasmon resonance and flow cytometry. NK cell activation was investigated by flow cytometry, and ADCC by lactate dehydrogenase release. The antitumor efficacy of F1M1 Fc-variants was investigated using TNBC cell xenografts in nude mice. NK cell recruitment, activation, and cytotoxic activity were analyzed in MDA-MB-231 cell xenografts by immunophenotyping and RT-qPCR. NK cells were depleted using an anti-asialo GM1 antibody. F1M1-Fc + antitumor effect was assessed in TNBC patient-derived xenografts (PDXs) and TNBC SUM159 cell xenografts, and in combination with paclitaxel or enzalutamide.

Results

Cath-D expression on the TNBC cell surface could be exploited to induce ADCC. F1M1 Fc-variants recognized human and mouse cath-D. F1M1-Fc + activated NK cells in vitro and induced ADCC against TNBC cells and cancer-associated fibroblasts more efficiently than F1M1. F1M1-Fc − was ineffective. In the MDA-MB-231 cell xenograft model, F1M1-Fc + displayed higher antitumor activity than F1M1, whereas F1M1-Fc − was less effective, reflecting the importance of Fc-dependent mechanisms in vivo. F1M1-Fc + triggered tumor-infiltrating NK cell recruitment, activation and cytotoxic activity in MDA-MB-231 cell xenografts. NK cell depletion impaired F1M1-Fc + antitumor activity, demonstrating their key role. F1M1-Fc + inhibited growth of SUM159 cell xenografts and two TNBC PDXs. In combination therapy, F1M1-Fc + improved paclitaxel and enzalutamide therapeutic efficacy without toxicity.

Conclusions

F1M1-Fc + is a promising immunotherapy for TNBC that could be combined with conventional regimens, including chemotherapy or antiandrogens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsAntineoplastic AgentsBenzamidesNitrilesPhenylthiohydantoinHumansAnimalsMicePaclitaxelCathepsin DMice, NudeCell Line, TumorAntibody-Dependent Cell CytotoxicityKiller Cells, NaturalImmunoglobulin Fc Fragments

Stichwörter der Autor:innen

ADCCNKTNBCenzalutamidehuman antibody-based therapypaclitaxelprotease

Substanzen

enzalutamidePaclitaxelCathepsin DAntineoplastic AgentsImmunoglobulin Fc FragmentsBenzamidesNitrilesPhenylthiohydantoin

Autor:innen und Institutionen

  • IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France.
  • Université de Tours - INRAE, UMR1282, Infectiologie et Santé Publique (ISP), équipe BioMédicaments Anti-Parasitaires (BioMAP), Tours, France.
  • RHEM, IRCM, Montpellier, France.
  • IRMB, University of Montpellier, INSERM, CNRS, CHU Montpellier, Montpellier, France.
  • Translational Research Unit, ICM, Montpellier, France.
  • Biometry Department, ICM, Montpellier, France.

ORCID-Profile: Pénélope Desroys du Roure, Laurie Lajoie, Aude Mallavialle, Lindsay B Alcaraz, Lise Fenou, Timothée David, Loïs Coenon, Florence Boissière-Michot, Marie-Christine Chateau, Giang Ngo, Marta Jarlier, Martin Villalba, Pierre Martineau, Valérie Laurent-Matha, Pascal Roger, Séverine Guiu, Thierry Chardès, Laurent Gros, Emmanuelle Liaudet-Coopman

Förderung

  • Inserm Transfert
  • Ligue Régionale du Gard
  • Ligue Régionale de l’Herault
  • Région Occitanie Pyrénées-Méditerranée
  • Agence Nationale de la Recherche
  • Université de Montpellier
  • Ligue Régionale de la Charente Maritime

Zitieren

APA

Desroys du Roure, P., Lajoie, L., Mallavialle, A., Alcaraz, L. B., Mansouri, H., Fenou, L., Garambois, V., Rubio, L., David, T., Coenon, L., Boissière-Michot, F., Chateau, M. C., Ngo, G., Jarlier, M., Villalba, M., Martineau, P., Laurent-Matha, V., Roger, P., Guiu, S., …, & Liaudet-Coopman, E. (2024). A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-007135

Vancouver

Desroys du Roure P, Lajoie L, Mallavialle A, Alcaraz LB, Mansouri H, Fenou L, et al. A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2023-007135

BibTeX
@article{DesroysduRoure2024,
  author = {Desroys du Roure, Pénélope and Lajoie, Laurie and Mallavialle, Aude and Alcaraz, Lindsay B and Mansouri, Hanane and Fenou, Lise and Garambois, Véronique and Rubio, Lucie and David, Timothée and Coenon, Loïs and Boissière-Michot, Florence and Chateau, Marie-Christine and Ngo, Giang and Jarlier, Marta and Villalba, Martin and Martineau, Pierre and Laurent-Matha, Valérie and Roger, Pascal and Guiu, Séverine and Chardès, Thierry and Gros, Laurent and Liaudet-Coopman, Emmanuelle},
  title = {A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  doi = {10.1136/jitc-2023-007135}
}
Kostenlos starten →